| Novan is a clinical development-stage biotechnology company focused on utilizing nitric oxide's naturally occurring anti-viral, anti-bacterial, anti-fungal and immunomodulatory mechanisms of action. Co.'s development pipeline includes: SB206, which is an anti-viral gel for the treatment of viral skin in fections, with a focus on molluscum contagiosum; SB204, which is a monotherapy for the treatment of acne vulgaris, a multi-factorial disease with multiple aspects of the disease pathology (anti-inflammatory and anti-bacterial); and SB208, which is an anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections. We show 23 historical shares outstanding datapoints in our coverage of NOVN's shares outstanding history.|
Understanding the changing numbers of NOVN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NOVN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NOVN by allowing them to research NOVN shares outstanding history
as well as any other stock in our coverage universe.